Hubei pharmaceutical industry based on advantages to promote upgrading

Recently, Hubei announced the action plan on accelerating the development of the pharmaceutical industry (hereinafter referred to as the plan) It is estimated that by 2017, the business income of pharmaceutical owners in the province will reach 160 billion yuan, with an average annual growth of 19% In recent years, Hubei's pharmaceutical industry has a good momentum of development, with a strong growth trend: first, the total scale has been expanding In 2012, the main business income of the province's pharmaceutical industry reached 67.4 billion yuan, an increase of 30.6% year-on-year, respectively 13 and 19 percentage points higher than the average growth of the province's industry and the national pharmaceutical industry The main business income of 10 enterprises has exceeded 1 billion yuan, and 17 enterprises have entered the national top 500 pharmaceutical companies Second, the advantages of the products are constantly highlighted The production of raw materials such as vitamin B1, B2 and taurine ranks first in the world, the number of amino acid varieties and export volume ranks first in China, the research and development and production of anesthetics ranks first in China, and the research and development and production of antiviral drugs, blood products and vaccines rank first in China Third, the innovation ability has been constantly improved At present, Hubei has 21 national and provincial enterprise technology centers and 9 national and provincial key laboratories Fourth, the potential for development is growing The construction of Biomedical Park and medical equipment Park in Wuhan National biological industry base is speeding up Six provincial pharmaceutical industrial parks, such as Ezhou and Yichang, have a good development momentum There are more than 90 projects under construction with a total investment of more than 30 billion yuan in the province's pharmaceutical industry The total planting area of traditional Chinese medicine in the province has reached more than 800000 mu, and the annual output of traditional Chinese medicine materials has reached more than 70000 tons But objectively, there are still many shortcomings in Hubei's pharmaceutical industry: the industrial scale is not very large, the enterprise scale is small, the main business income of the pharmaceutical enterprises in the whole province is 231 million yuan, lower than the average value of 271 million yuan in the whole country; the product structure is not good, the high value-added varieties of pharmaceutical products are few, and the export is mainly raw materials; the independent innovation ability of enterprises is limited, and the development of new products is mostly imitated There are few products with independent intellectual property rights According to the current situation of Hubei Medical industry, the plan requires efforts from four aspects One is to highlight four key points, improve the industrial chain and expand the scale of the industry We will make breakthroughs in developing the biomedical industry, expand and strengthen the modern industry of traditional Chinese medicine, and vigorously develop the industries of new preparations, medical devices and biomedical materials Second, we should vigorously promote independent innovation, promote the integration of "two modernizations" and "two types" development, and enhance the ability of independent innovation of enterprises To guide and encourage pharmaceutical enterprises with conditions to set up new drug R & D centers, accelerate the R & D and innovation of new products, promote the industry to the high-end development of the value chain, strengthen the technological transformation of enterprises, promote the deep integration of informatization and pharmaceutical industry, strengthen energy conservation and emission reduction, eliminate the backward production capacity of chemical APIs, and build resource-saving and environment-friendly pharmaceutical enterprises and parks Third, we will unswervingly adjust the structure, realize resource agglomeration, enterprise grouping and industrial clustering We should strengthen the integration of resources, effectively integrate the existing product variety number resources in the province, realize the transfer of drug production number (approval document) to the advantageous enterprises; encourage the upstream and downstream integration between enterprises, improve the industrial chain, support and support the construction of a number of major projects of enterprises, and accelerate the construction of pharmaceutical industry base The fourth is to undertake new industries, cultivate big brands and achieve great development in the process of expanding opening up We will strengthen quality and safety supervision, strengthen the construction of the credit system for drug safety and the capacity-building of drug safety monitoring.